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Purpose of the review  
Several members of the Fibroblast Growth Factor (FGF) family have been identified as 
key regulators of energy metabolism in rodents and non-human primates. Translational studies 
show that their metabolic actions are largely conserved in humans, which led to the 
development of various FGF-based drugs, including FGF21-mimetics LY2405319, PF-
05231023 and Pegbelfermin, and the FGF19-mimetic NGM282. Recently, a number of clinical 
trials have been published that examined the safety and efficacy of these novel therapeutic 
proteins in the treatment of obesity, type 2 diabetes (T2D), nonalcoholic steatohepatitis 
(NASH), and cholestatic liver disease. In this review, we discuss the current understanding of 
FGFs in metabolic regulation and their clinical potential.  
 
Recent findings  
 FGF21-based drugs induce weight loss and improve dyslipidemia in patients with 
obesity and type 2 diabetes (T2D), and reduce steatosis in patients with NASH. FGF19-based 
drugs reduce steatosis in patients with NASH, and ameliorate bile acid (BA)-induced liver 
damage in patients with cholestasis. In contrast to their potent anti-diabetic effects in rodents 
and non-human primates, FGF-based drugs do not appear to improve glycemia in humans. In 
addition, various safety concerns, including elevation of low-density lipoprotein cholesterol 




Clinical trials with FGF-based drugs report beneficial effects in lipid and BA 
metabolism, with clinical improvements in dyslipidemia, steatosis, weight loss, and liver 




• FGFs potently interfere with bile acid, lipid and carbohydrate metabolism in rodents 
and non-human primates. 
• Translational studies support a role for FGFs in metabolic regulation and disease in 
humans.  
• Clinical studies demonstrate that FGF-based drugs effectively ameliorate dyslipidemia, 
hepatic steatosis, and BA-related liver damage, while their glycemic actions are not 















FGF15/19, FGF21, and more recently FGF1 have emerged as key regulators of BA, 
lipid, and carbohydrate metabolism (1–3). These ‘metabolic FGFs’ are members of the FGF 
superfamily, which consists of eighteen closely related genes, and of which the encoded 
proteins can be functionally classified as autocrine/paracrine or endocrine acting growth factors 
(4). FGF1 is an autocrine/paracrine growth factor that binds locally to cell surface heparan 
sulfate proteoglycans (HSPG) (5). FGF19 and FGF21 have reduced affinity for HSPG, which 
allows them to escape into the circulation and act as endocrine hormones (6). Instead of binding 
to HSPG, endocrine FGFs bind to the transmembrane protein β-klotho (KLB) (6). Recruitment 
of FGFs by HSPG or KLB promotes FGF receptor (FGFR) transphosphorylation, followed by 
activation of various signaling cascades, including the RAS-MAPK, PI3K-AKT, PLCγ, and 
STAT pathways (4). In both humans and mice, four FGFR genes (FGFR1-4) have been 
identified, which differ in their ligand binding-specificities (7). As FGFs and FGFRs are 
ubiquitously expressed and regulate basic cellular functions, including growth, proliferation, 
and differentiation (8), many FGF/FGFR mutations lead to defective embryonic development 
(4). However, the phenotypes of Fgf15, Fgf21, and Fgf1 knockout mice revealed that these 
genes also play important roles postnatally in controlling metabolic homeostasis (9–11). The 
metabolic function of these genes is also highlighted by their identification as targets of 
nutrient-sensitive transcription factors, including farnesoid X receptor (FXR) and peroxisome 
proliferator-activated receptors alpha and gamma (PPARα, PPARγ) (1). Translational studies 
further demonstrated that FGFs regulate similar metabolic pathways in humans, which led to 
the development of various FGF-based drugs, of which the safety and efficacy are currently 
being evaluated (3). In this review, we will give an overview of the current understanding of 
FGFs in metabolic regulation (figure 1), and discuss the therapeutic effects of FGF-based drugs 
in human disease (table 1). 
 
FGF15/19: biological functions  
Despite the low sequence similarity between mouse Fgf15 and its human orthologue 
Fgf19 (12,13), their genes are syntenic and their biological function in the regulation of BA 
homeostasis is conserved (9,14). Postprandial release of BAs activates ileal FXR and results in 
the production of FGF15/19 (9,14). Once secreted, FGF15/19 travels to the liver where it binds 
the KLB/FGFR4 complex to inhibit the activity of cholesterol 7 alpha-hydroxylase (CYP7A1), 
the first and rate-limiting enzyme in the conversion of cholesterol to BAs (9). Since BAs are 
strong detergents, their synthesis needs to be tightly regulated to prevent enterohepatic damage 
(15). As discussed later, the ability of FGF15/19 to inhibit BA synthesis is therapeutically 
exploited to prevent BA-induced tissue damage in cholestasis and NASH. 
FGF15/19 signaling also modulates lipid- and carbohydrate metabolism (16). 
Transgenic mice that overexpress FGF19 display increased energy expenditure and are 
protected against diet-induced obesity and steatosis, at least partly by increasing fatty acid 
oxidation, but also by decreasing de novo lipogenesis (17-20). A role for FGF19 in glucose 
homeostasis is reflected by its ability to reduce plasma glucose levels in diabetic mice (21). 
This glucose lowering effect has been mechanistically linked to a glycogen synthase kinase 3 
(GSK-3)-dependent increase in hepatic glycogen storage (22), and a cAMP regulatory element 





α)-dependent decrease in hepatic gluconeogenesis (23). However, extrahepatic mechanisms, in 
particular KLB/FGFR1-dependent neuronal effects, also appear to contribute to FGF19-driven 
glucose lowering (24–26). 
 
FGF19: human association studies 
Altered plasma levels of FGF19 are observed in several physiological and 
pathophysiological states. Physiologically, FGF19 follows a diurnal rhythm and is increased 
postprandially following BA-induced FXR activation, as evidenced by the effects of primary 
BAs and BA-binding resins that increase and decrease serum FGF19 levels, respectively (14). 
Besides its presence in serum, FGF19 is  expressed in cholangiocytes and secreted into human 
bile, yet the physiological relevance of this is not known (27,28). Reduced levels of FGF19 are 
generally observed in obesity and related disorders, including T2D, gestational diabetes, non-
alcoholic fatty liver disease (NAFLD) and (NASH) (30-34), but also in conditions of BA 
malabsorption such as cystic fibrosis (31–33). During cholestasis, both hepatic and serum 
FGF19 are dramatically increased, indicating an adaptive response aimed to reduce BA-induced 
liver damage (34–36). Although FGF19 levels sometimes normalize after bariatric surgery, its 
contribution to surgery-dependent diabetes remission is still debated (31,32,37).  
 
FGF19: clinical trials  
Although preclinical and translational studies with FGF19-mimetic drugs have shown 
promising results, the clinical application has been impeded by the fact that chronic FGF19 
exposure in mice induces hepatocyte proliferation and the development of hepatocellular 
carcinomas (HCC), mediated through activation of the FGFR4/IL6/STAT3-pathway (38,**39). 
Extensive protein engineering produced a non-mitogenic FGF19 variant (NGM282, also 
referred to as M70) (19) which lacks FGFR4/IL6/STAT3 activity while retaining the ability to 
suppress CYP7A1 and BA synthesis in animal models (40). A proof-of-concept study involving 
healthy volunteers examined the ability of NGM282 to suppress BA synthesis in humans and 
reported strongly reduced serum 7α-hydroxy-4-choleston-3-one (C4) levels, a surrogate marker 
of hepatic CYP7A1 activity (47, **48). In the fed state, decreased serum C4 levels were 
associated with significantly lower serum BA concentrations, providing direct evidence of the 
role of the FGF19 pathway in human BA metabolism (40). In a follow-up study, NGM282 was 
reported to have multiple beneficial effects in NASH. In this phase 2 trial, biopsy-confirmed 
NASH patients were treated with NGM282 for 12 weeks, which resulted in a clinically relevant 
decrease in liver fat content in up to 86% of the patients and this was accompanied by a 
reduction in plasma triglyceride (TG) levels and markers of liver damage and fibrosis (**42). 
In contrast to rodent studies, glucose, Hba1c, and insulin levels were unaffected (**42,43). A 
possible safety concern of NGM282 in NASH is its ability to increase plasma LDLc levels 
(**42). Nevertheless, NGM282-dependent elevations in cholesterol levels can be effectively 
managed by concomitant use of rosuvastatin (*44).  
Two recent studies evaluated the effect of NMG282 in patients with primary biliary 
cholangitis (PBC) and primary sclerosing cholangitis (PSC), which are chronic liver diseases 
characterized by BA-induced liver damage and limited therapeutic options (45). In PBC 
patients, NGM282 significantly reduced alkaline phosphatase (ALP) levels (**46), a serum 
marker that strongly correlates with disease progression (**48,*49). In addition, NGM282 also 




robustly reduced liver damage markers, including gamma-glutamyl transpeptidase (GGT), 
alanine aminotransferase (ALT), and aspartate aminotransferase (AST), and lowered 
immunoglobulin levels, suggesting reduced disease-related immune activity (**46). Similarly, 
in PSC patients, NGM282 reduced serum levels of C4 levels, BAs, and markers of liver damage 
and fibrosis (**48). However, plasma ALP levels were only transiently reduced (**48). 
Even though NGM282 was well tolerated in most patients, a dose-dependent increase 
in abdominal cramping and diarrhea was observed in all study populations (42,**46,*49). This 
appears to be caused by an effect of NGM282 on bowel function, gastric emptying, and colonic 
transit, and is speculated to be mechanistically unrelated to its effects on BAs, but rather by 
actions on nerve cells (*49). In addition, rodent studies suggest that FGF19 can activate 
metabolic pathways that are utilized by FGF21 (24), indicating that additional mechanisms 
could play a role as well.  
 
FGF21: biological functions 
The metabolic activity of FGF21 was originally discovered in a cell-based screen in 
which it stimulated glucose uptake in adipocytes (50). Subsequent in vivo studies demonstrated 
that FGF21 improved insulin sensitivity and lowered TG levels in diabetic rodents (50). Long-
term FGF21 treatment largely recapitulates these metabolic improvements, but also lowers 
body weight by enhancing energy expenditure without affecting food intake (51–53). Similarly, 
transgenic or adenoviral overexpression of FGF21 protects against diet-induced obesity and 
steatosis, improves insulin sensitivity and even enhances longevity in mice (50,54–56). 
Conversely, genetic deficiency or knockdown of FGF21 induces weight gain, glucose 
intolerance and dyslipidemia (57,58). In diabetic rhesus monkeys, therapeutic administration of 
FGF21 induced similar metabolic improvements, including decreased plasma levels of glucose, 
insulin, TG, and LDLc, while it increased plasma high-density lipoprotein cholesterol (HDLc) 
(59). Several mechanisms have been implicated in the pharmacological actions of FGF21, in 
particular, the activation of the KLB/FGFR1 complex in adipose tissue and brain (24,60–
63,**64-68). 
In addition to its intricate pharmacological effects, the physiological actions of FGF21 
appear equally complex. Although FGF21 is predominantly expressed in the liver, it is also 
expressed in other tissues including, white and brown adipose tissues (WAT and BAT), 
pancreas and muscle (69). Various types of nutrient stress have been shown to induce FGF21 
expression in a tissue-specific manner. Both prolonged fasting and ketogenic diets strongly 
increased hepatic FGF21 expression (56,57,70). Fasting increases FGF21 expression in 
PPARα-dependent manner, and is closely linked with changes in lipolysis, ketogenesis, growth, 
torpor, and female reproduction, all considered to be aspects of the adaptive starvation response 
(56,57,71). A role for FGF21 in fasting is further supported by its mutual interactions with 
glucagon (50,72,73). Besides fasting, high-carbohydrate diets and fasting-refeeding regimens  
also stimulate FGF21 expression in liver and WAT (74–79). However, the physiological 
significance of feeding-mediated induction of FGF21 is not fully understood (74). Finally, cold 
exposure increases FGF21 in BAT and WAT, where it appears to modulate thermogenic 







FGF21: human association studies 
While FGF21 mediated aspects of the adaptive starvation response in rodents, it remains 
unclear if it has a similar function in humans. A ketogenic diet or fasting up to 72h does not 
appear to increase serum FGF21 levels in humans (83–85). Even in anorexia nervosa, a state of 
chronic nutritional deprivation, serum FGF21 levels are only slightly reduced as compared to 
normal-weight controls (86,87). Only after prolonged fasting for 7 or 10 days, circulating 
FGF21 levels appear to be moderately increased (88,89). In contrast to starvation, a variety of 
other metabolic stressors, including high carb diets, fructose, and protein restriction, appear to 
modulate circulating FGF21 levels more clearly (90–95). The identification of an FGF21 gene 
variant that is associated with increased sugar intake  further highlights a role for FGF21 in the 
central regulation of carbohydrate consumption (92).  
Increased levels of FGF21 are generally associated with  obesity-related diseases 
including T2D, hypertension, coronary heart disease, and NAFLD/NASH(85,96–98). In 
addition, FGF21 levels are mainly associated with BMI and adiposity, but not with insulin 
resistance (85,99,100). At the same time, obesity is associated with a decrease in FGFR and 
KLB expression, possibly reflecting a state of receptor desensitization that is counteracted by 
enhanced FGF21 production (101). It remains controversial, however, whether chronically 
elevated FGF21 levels reflect a state of ‘’FGF21 resistance’’, in particular since therapeutic 
strategies that enhanced FGF21 levels, such as gastric bypass, dietary interventions, and 
pharmacological administration, improve metabolic health (102–*107). 
 
FGF21: clinical trials 
Although the development of an FGF21-based drug has not been hampered by potential 
mitogenic effects, native FGF21 has poor pharmacokinetic properties due to proteolytic 
degradation and its tendency to aggregate (108). Efforts to optimize production and stability 
led to the development of LY2405319 by Eli Lilly, the first FGF21-based drug tested in humans 
(108). In patients with obesity and T2D, daily injections of LY2405319 for 28 days resulted in 
a less atherogenic apolipoprotein profile, reduced body weight and fasting insulin levels and 
increased adiponectin levels (109). In contrast to rodents and non-human primates, however, 
no glucose lowering effects were observed (109).  
Similar efforts by Pfizer to improve FGF21 bioavailability led to the development of 
PF-05231023, which consists of two recombinant FGF21 molecules linked to the Fab portion 
of a scaffold antibody (110,111). In obese people with T2D, PF-05231023 significantly reduced 
body weight, plasma TGs, and LDLc, while increasing HDLc. Although PF-05231023 also 
potently stimulated plasma adiponectin levels, glycemia was not improved (*112,113). Possible 
safety concerns of PF-05231023 treatment are its ability to affect markers of bone homeostasis 
and blood pressure (*112).  
More recently, the outcomes of clinical trials with Pegbelfermin (BMS-986036), a 
polyethylene glycol-modified (PEGylated) recombinant human FGF21 analog developed by 
Bristol-Myers Squibb, have been published. A 12 week phase 2 study with daily or weekly 
administration of Pegbelfermin in patients with obesity and T2DM, showed significant 
improvements in HDLc and TGs, while no statistically significant improvements were found 
in HbA1c levels, weight loss, fasting insulin, C-peptide, and measures of hepatic insulin 
sensitivity (HOMA-IR and QUICKI) (114). In a 16 week phase 2a clinical trial with NASH 




patients, Pegbelfermin significantly decreased the hepatic fat fraction, which was associated 
with a reduction in markers of hepatic injury and fibrosis (**115). 
Collectively, these studies show that FGF21-based drugs have the ability to control 
dyslipidemia and steatosis in humans, while their ability to control glycemia, similar to FGF19-
based drugs, appear limited. The ongoing development of novel FGF-based therapeutics, such 
as the KLB/FGFR1 directed monoclonal antibody NGM313 (116–119) and FGF1-based drugs 
(120,121), may provide the ability to target glycemia more effectively.  
 
FGF1: biological functions  
A role for FGF1 in metabolism was uncovered by its identification as a target of nuclear 
receptor PPARγ (11). FGF1 is highly upregulated in WAT following a high-fat diet (HFD) 
challenge, and FGF1 knockout mice display an aggressive diabetic phenotype in response to an 
HFD, caused by defective adipose remodeling and expansion (11). In a follow-up study, it was 
demonstrated that pharmacological administration of recombinant FGF1 effectively lowers 
blood glucose levels in diabetic mouse models (120,121). Mechanistically, this glucose 
lowering effect was dependent on adipose FGFR1, highlighting the role of adipose tissue 
function in this process (120). The intriguing finding that intracerebroventricular injections of 
FGF1 can normalize blood glucose levels up to 18 weeks indicates that FGF1 also has central 
actions, similar to FGF19 and FGF21 (26,122,**123).  
In addition to its potent glucose-lowering effects, peripheral FGF1 injections also 
reduced obesity-related hepatic steatosis and inflammation (120,121,124). In ob/ob mice, FGF1 
reduced steatosis in a zonated manner, with a pronounced reduction in the periportal zone, but 
not pericentrally, arguing for a role of FGF1 in stimulating either fatty acid oxidation or very 
low-density lipoprotein (VLDL) secretion (124). Supporting this notion, choline-deficient 
mice, which are defective in hepatic lipid catabolism, were refractory to the anti-steatotic effects 
of FGF1 (124). In contrast, the anti-inflammatory effects of FGF1 were still preserved in 
choline-deficient mice, suggesting that FGF1-mediated suppression of hepatic inflammation is 
independent of its anti-steatotic effects (124). 
 
FGF1: human association studies 
Obesity is associated with increased FGF1 expression in both omental and subcutaneous 
adipose tissue (125–127). In both humans and rodents, adipocytes have been identified as the 
main FGF1 producing cell type (125–127). In contrast to the endocrine FGFs, locally produced 
FGF1 it is not secreted into the circulation (125–127). Interestingly, although obesity increases 
FGF1 expression in adipose tissue, weight loss does not reduce adipose FGF1 levels (127), 
supporting the notion that, in addition to promoting adipose tissue expansion, FGF1 also has a 
role in its contraction (11). Different cell types and processes may be underlying the 
autocrine/paracrine effects of FGF1 on adipose tissue function, including activation, 
differentiation, and proliferation of adipocytes and endothelial cells (11, 110-*112).  
 
FGF1: clinical trials 
Because of its potent angiogenic effects, clinical trials with FGF1 have primarily 
focused on the treatment of ischemia and wound healing, while its therapeutic potential in the 





stability, potential mitogenic effects of FGF1 are an important obstacle in the development of 
FGF1-based drugs as well (121). Attempts to reduce mitogenic activity has yielded several 
FGF1 variants including R50E (134), FGF1dNT (120), and FGF1dHBS (121). Although 
quantitative differences in FGF1-FGFR dimer stability clearly contribute to the mitogenic 
effects of wildtype and mutant FGF1 (121), qualitative differences in pathway activation, or 
differences in nuclear translocation (135,136), could also play a role.  
 
Conclusion 
Current evidence shows that FGF-based drugs can effectively ameliorate dyslipidemia, 
hepatic steatosis, and BA-related liver damage. However, anti-diabetic effects, as observed in 
rodents and non-human primates, are currently not recapitulated in humans studies. The lack of 
these anti-diabetic effects might be due to the existence of differences in glucose regulation 
between species (137). In addition, it is well-described that numerous pathological conditions, 
such as obesity (101) and inflammation (138), are associated with reduced KLB expression, 
which might limit FGF19 and FGF21 responsiveness. Furthermore, the use of FGF-based drugs 
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Figure 1: The physiological and pharmacolgical actions of FGF19, FGF21, and FGF1 are driven by activation of 







Table 1: Key findings of clinical trials using FGF-based drugs 
FGF-based 
drug 
Dose Disease Key findings References 
NGM282 
(FGF19) 
3mg/day (7 days) Healthy 
volunteers 
↓ C4 and serum BAs. (40) 
 3 or 6mg/day (12 
weeks) 
NASH ↓ liver fat content, ALT, AST, 
C4, Pro-C3, TIMP-1, TGs, body 
weight.  
↑ LDL.  
(**42) 
 0.3 or 3mg/day (28 
days) 
PBC ↓ ALP, GGT, ALT, AST, LDL, 
C4, IgM, IgG, GCA. 
(**46) 
 1 or 6mg/day (14 
days) 
FC ↓ GE T1/2, fecal Bas.  
↑ CT, #BM, stool form, ease of 
passage. 
(*49) 
 1 or 3mg/day (12 
weeks) 
PSC ↓ C4, serum BAs, ALT, AST, 









NASH ↓ C4, serum BA, TGs, total 






3, 10, or 20mg/day 
(28 days) 
T2D ↓ LDL, ApoA2, ApoB, ApoC3, 
TGs, total cholesterol, insulin, 
body weight.  







T2D ↓ TGs, LDL, total cholesterol.  
↑ HDL.  
(110) 
 
5-140mg (twice a 
week, for 5 weeks) 
T2D ↓ body weight, TGs, total 
cholesterol, LDL.  
↑ HDL, adiponectin. IGF-1.  
(113) 
 
25, 50, 100 or 150 









10 mg daily or 20 
mg weekly (for 16 
weeks) 
NASH ↓ body fat, hepatic lipids, TGs, 




1, 5, 20mg daily or 




↓ TGs, pro-C3. 
↑ HDL, adiponectin.  
 
(114) 
T2D, type 2 diabetes; NASH, non-alcoholic steatohepatitis, PBC, primary biliary cholangitis, FC, functional 
constipation; PSC, primary sclerosing cholangitis; LDL, low-density lipoprotein, ApoA2, apolipoprotein A2; 
ApoB, apolipoprotein B; ApoC3, Apolipoprotein C-III; TGs, triglycerides; HDL, high-density lipoprotein; C4, 7-
alpha-hydroxy-4-cholesten-3-one; Bas, bile acids; IGF-1, insulin-like growth factor 1; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; Pro-C3, neoepitope-specific N-terminal pro-peptide of type 
III collagen; TIMP-1, tissue inhibitor of metalloproteinase 1; ALP, alkaline phosphatase; GGT, gamma-glutamyl 




transpeptidase; IgM, immunoglobulin M; IgG, immunogloblulin G; GCA, glycocholic acid; GE T1/2, gastric 
emptying; CT, colonic transit; BM, bowel movements; PIIINP, n-terminal propeptide of type III collagen.  
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